Yun Chon
Amgen
22 Papers
102 Citations
Yun Chon is an academic researcher from Amgen. The author has contributed to research in topics: Asthma & Medicine. The author has an hindex of 13, co-authored 20 publications.
Chat about Author
Papers
Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
TL;DR: Inhibition of IL-17 receptor A did not produce a treatment effect in subjects with asthma and the results of the high-reversibility subgroup analysis are of uncertain significance, requiring further study of brodalumab in this asthma subpopulation.
625
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R. Targan,Brian G. Feagan,Severine Vermeire,Remo Panaccione,Gil Y. Melmed,Carol J. Landers,Dalin Li,Chris B. Russell,Richard Newmark,Nan Zhang,Yun Chon,Yi-Hsiang Hsu,Shao-Lee Lin,Paul Klekotka +13 more
TL;DR: Treatment with brodalumab resulted in a disproportionate number of cases of worsening CD in patients with active CD and no evidence of meaningful efficacy, and analyses did not suggest additional safety risks of brodalUMab beyond worsening of CD symptoms in patientsWith active CD.
338
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation
Eli O. Meltzer,William W. Busse,Sally E. Wenzel,Vasily Belozeroff,Haoling H. Weng,JingYuan Feng,Yun Chon,Chiun-Fang Chiou,Shao-Lee Lin +8 more
TL;DR: The utility of the composite ACQ score measurement to predict risk of future exacerbation in clinical trials and clinical practice is found to be a better predictor of future risk than individual ACQ components.
143
•Journal Article
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
Joan M. Bathon,Roy Fleischmann,Désirée van der Heijde,John Tesser,Paul M. Peloso,Yun Chon,Barbara White +6 more
TL;DR: Consistent with responses in younger subjects, elderly subjects with RA treated with etanercept experienced significant improvement in disease activity and function without incurring additional safety concerns.
139
Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Stephan R. Targan,Brian G. Feagan,Severine Vermeire,Remo Panaccione,Gil Y. Melmed,Consuelo Blosch,Richard Newmark,Nan Zhang,Yun Chon,Shao-Lee Lin,Paul Klekotka +10 more
88